BAL lymphocytosis as a predictive marker for drug response and long-term outcome in fibrotic ILD: systematic review
Authors:
Open Access
- 4 June 2026
- journal article
- review article
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004035
Abstract
Background: Fibrotic interstitial lung diseases (fILDs) encompass a heterogeneous group of disorders characterised by varying degrees of inflammation and/or fibrosis. The role of bronchoalveolar lavage lymphocytosis (BALL) as a prognostic biomarker and predictor of corticosteroid (CS) response remains uncertain. We investigated whether, in patients with fILD, increased BALL can serve as a marker for CS responsiveness and whether increased BALL may also predict better long-term outcomes following CS therapy compared with patients with lower BALL levels. Methods: A systematic review was conducted. MEDLINE, Embase, Web of Science and Google Scholar were searched up to 4 August 2025. Eligible studies included mainly observational clinical studies evaluating BALL in fILD, with a focus on short-term CS response (6 months) after treatment, including changes in lung function parameters, radiological response and overall and progression-free survival. Study selection, data extraction and quality assessment were performed independently by two reviewers. Disagreements were resolved by consensus. Results: 30 studies involving a total of 3083 patients were included. Increased BALL was associated with better CS response as reflected by improved lung function and increased survival in fILD subtypes, such as hypersensitivity pneumonitis and non-specific interstitial pneumonia. However, BALL thresholds varied, and study heterogeneity precluded meta-analysis. Most studies showed moderate to high risk of bias. Conclusions: Increased BALL may predict CS responsiveness and treatment outcome prediction in fILD; however, clinical implementation remains limited due to insufficient evidence, predominantly observational studies, inconsistent BALL thresholds and heterogeneous results across disease entities. Standardisation and prospective validations are needed to better integrate BALL findings into clinical routine. PROSPERO registration number: CRD420251057631.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (10006062)
This publication has 78 references indexed in Scilit:
- BAL Fluid Cellular Analysis and Radiologic Patterns in Patients With Fibrotic Interstitial Lung DiseaseChest, 2024
- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic DiseasesArthritis & Rheumatology, 2024
- Meta‐analysis and traditional systematic literature reviews—What, why, when, where, and how?Psychology & Marketing, 2022
- Prognostic significance of bronchoalveolar lavage cellular analysis in patients with acute exacerbation of interstitial lung diseaseRespiratory Medicine, 2021
- Bronchoalveolar lavage differential cell count on prognostic assessment of patients with stable or acute interstitial lung disease: A retrospective real-life studyClinical Immunology, 2020
- Acute exacerbation of interstitial lung disease after proceduresRespiratory Medicine, 2019
- Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective studyRespiratory Medicine, 2017
- Factors associated with the relapse of cryptogenic and secondary organizing pneumoniaRespiratory Investigation, 2016
- Acute exacerbation of IPF following diagnostic bronchoalveolar lavage proceduresRespiratory Medicine, 2012
- Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis–associated interstitial lung disease are not predictive of disease progressionArthritis & Rheumatism, 2007